Treatment of acquired factor X inhibitor by plasma exchange with concomitant intravenous immunoglobulin and corticosteroids

American Journal of Hematology

Volumn 83, Issue 4, 2008, Pages 318-320

  Hsia, Cyrus C ^a   Keeney, Mike ^b   Bosco, Annmarie A ^a   Xenocostas, Anargyros ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; FRESH FROZEN PLASMA; IMMUNOGLOBULIN G; PREDNISONE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; VITAMIN K GROUP;

ADULT; ARTICLE; BLEEDING; BLOOD CLOTTING FACTOR 10 DEFICIENCY; CASE REPORT; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; ENZYME LINKED IMMUNOSORBENT ASSAY; EPISTAXIS; HEMATOCHEZIA; HEMATURIA; HUMAN; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; LYMPHADENOPATHY; MALE; PARTIAL THROMBOPLASTIN TIME; PLASMAPHERESIS; PRIORITY JOURNAL; RETROPERITONEAL HEMORRHAGE;

CARCINOMA, BRONCHOGENIC; COMBINED MODALITY THERAPY; FACTOR X; FACTOR X DEFICIENCY; HEMORRHAGIC DISORDERS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; LUNG NEOPLASMS; LYMPHATIC DISEASES; MALE; MIDDLE AGED; PLASMA EXCHANGE; PREDNISONE; VIRUS DISEASES;

EID: 41449094467     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21105     Document Type: Article

References (17)

1. Peyvandi F, Mannucci PM. Rare coagulation disorders. Thrombosis and Haemostasis 1999;82:1207-1214
2. Herrmann FH, Auerswald G, Ruiz-Saez A, et al. The Greifswald Factor X Deficiency Study Group. Factor X deficiency: Clinical manifestation of 102 subjects from Europe and Latin America with mutations in the factor 10 gene. Haemophilia 2006;12:479-489.
3. Choufani EB, Sanchorawala V, Ernst T, et al. Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: Incidence, bleeding manifestations, and response to high-dose chemotherapy. Blood 2001;97:1885-1887.
4. Smith SV, Liles DK, White GC II, Brecher ME. Successful treatment of transient acquired factor X deficiency by plasmapheresis with concomitant intravenous immunoglobulin and steroid therapy. Am J Hematol 1998;57:245-252.
5. Rao LV, Zivelin A, Iturbe I, Rapaport SI. Antibody-induced acute factor X deficiency: Clinical manifestations and properties of the antibody. Thromb Haemost 1994;72:363-371.
6. Lankiewicz MW, Bell WR. A unique circulating inhibitor with specificity for coagulation factor X. Am J Med 1992;93:343-346.
7. Mulhare PE, Tracy PB, Golden EA, et al. A case of acquired factor X deficiency with in vivo and in vitio evidence of inhibitor activity directed against factor X. Am J Clin Pathol 1991;96:196-200.
8. Kyriakou DS, Alexandrakis MG, Passam FH, et al. Acquired inhibitors to coagulation factors in patients with gastrointestinal diseases. Eur J Gastroenterol Hepatol 2002;14:1383-1387.
9. Ashrani AA, Aysola A, Al-Khatib H, et al. Lupus anticoagulant associated with transient severe factor X deficiency: A report of two patients presenting with major bleeding complications. Br J Haematol 2003;121:639-642.
10. Hedner U. Recombinant activated factor VII as a universal haemostatic agent. Blood Coagul Fibrinolysis 1998;9 (Suppl 1):S147-S152.
11. Colman RW,Marder VJ,Clowes AW, editors. Hemostasis and Thrombosis: Basic Principles and Clinical Practice,5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2006. pp 1075-1076.
12. Lisman T, De Groot PHG. Mechanism of action of recombinant factor VIIa. J Thromb Haemost 2003;1:1138-1139.
13. ten Cate H, Bauer KA, Levi M et al. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest 1993;92:1207-1212.
14. Mittal S, Watson HG. A critical appraisal of the use of recombinant factor VIIa in acquired bleeding conditions. Br J Haematol 2006;133:355-363.
15. Fischer KG, Deschler B, Lubbert M. Acquired high-titer factor VIII inhibitor: Fatal bleeding despite multimodal treatment including rituximab preceded by multiple plasmaphereses. Blood 2003;101:3753-3754.
16. Fu YX, Kaufman R, Rudolph AE, et al. Multimodality therapy of an acquired factor V inhibitor. Am J Hematol 1996;51:315-318.
17. Zehnder JL, Leung LL. Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin. Blood 1990;76:2011-2016.